Topic: phase 2 trial

mRNA Cancer Vaccine Shows 5-Year Protection, Moderna-Merck Data Reveals

A personalized mRNA vaccine combined with standard immunotherapy nearly halved the risk of recurrence or death in high-risk melanoma patients over five years compared to immunotherapy alone. The vaccine is custom-made for each patient using genetic markers from their tumor to train the immune sys...